Gaithersburg-based Viela Bio Inc. has filed to begin trading publicly with a $150 million initial public offering, fast bringing the business full circle after its spinout from MedImmune in early 2018.
The biotech applied to trade on the Nasdaq Global Market under the ticker symbol "VIE" and plans to offer a little more than 37 million shares to the public, including 393,780 shares of unvested restricted stock subject to repurchase.
Viela did not disclose an estimated share price or date for…
